Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-26T02:03:38.369Z Has data issue: false hasContentIssue false
  • English
  • Français

In vivo study of a reserved atrial septal puncture area patent foramen ovale occluder

Published online by Cambridge University Press:  06 September 2022

Haibin Jiang Open the ORCID record for Haibin Jiang [Opens in a new window] ,
Suyan Cao ,
Renrong Wang ,
Shuya Wang ,
Ziqian He ,
Xin Xu ,
Chengjian Yang  and
Xiaoxiao Liu
Haibin Jiang
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
Suyan Cao
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
Renrong Wang
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
Shuya Wang
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
Ziqian He
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
Xin Xu
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
Chengjian Yang
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
Xiaoxiao Liu*
Affiliation:
Department of Cardiology, Wuxi NO. 2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China
*
Author for correspondence: Xiaoxiao Liu, Department of Cardiology, Wuxi NO.2 People’s Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu, China. E-mail: pjclxx@163.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Purpose:

After patent foramen ovale interventional closure, puncture of the interatrial septum through the occluder is difficult but sometimes needed for further interventional treatment. This paper presents findings from an in vivo experimental study of a reserved atrial septal puncture area patent foramen ovale occluder.

Materials and methods:

A patent foramen ovale model was established in canines using trans-septal puncture of the fossa ovale and high-pressure balloon dilation. Then, patent foramen ovale closure was performed with a reserved atrial septal puncture area and all canines were raised for 3 months. Then, the occluder was crossed and left atrial angiography was performed on the septal area with the occluder. Finally, DSA angiography, echocardiography, and histology were used to evaluate the performance and feasibility of the reserved atrial septal puncture area.

Results:

A patent foramen ovale model was successfully established in 10 canines using the atrial septal puncture method. The average diameter of the patent foramen ovale was 3.77 ±0.19 mm, and the patent foramen ovale was successfully closed in all canines using a reserved atrial septal puncture area. As assessed using transoesophageal echocardiography, the new occluder exhibited an ideal position and was occluded entirely without a residual shunt intraoperatively and postoperatively. A 100% success rate of atrial septum puncture was achieved across the new occluder. The occluders were completely endothelialised 3 months post-implantation.

Conclusions:

The reserved atrial septal puncture area was effective in patent foramen ovale closure and exhibited positive sealing performance and biological compatibility. Trans-septal puncture was feasible and effective after reserved atrial septal puncture area patent foramen ovale closure.

Keywords

patent foramen ovaleatrial septostomyinterventional closurereserved atrial septostomy area occluder
Type
Original Article
Information
Cardiology in the Young , Volume 33 , Issue 9 , September 2023 , pp. 1581 - 1586
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Horlick, E, Kavinsky, CJ, Amin, Z, et al. SCAI expert consensus statement on the operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: the american academy of neurology affirms the value of this statement as an educational tool for neurologists. Catheter Cardiovasc Interv 2019; 93: 859–874.10.1002/ccd.28111CrossRefGoogle ScholarPubMed
Kuramoto, J, Kawamura, A, Dembo, T, et al. Prevalence of patent foramen ovale in the japanese Population-Autopsy study. Circ J 2015; 79: 2038–2042.10.1253/circj.CJ-15-0197CrossRefGoogle ScholarPubMed
Mas, JL, Derumeaux, G, Guillon, B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017; 377: 1011–1021.10.1056/NEJMoa1705915CrossRefGoogle ScholarPubMed
Ning, M, Lo, EH, Ning, PC, et al. The brain’s heart-therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease. Pharmacol Ther 2013; 139: 111–123.10.1016/j.pharmthera.2013.03.007CrossRefGoogle Scholar
Schnabel, RB, Yin, X, Gona, P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the framingham heart study: a cohort study. Lancet 2015; 386: 154–162.10.1016/S0140-6736(14)61774-8CrossRefGoogle ScholarPubMed
Chugh, SS, Havmoeller, R, Narayanan, K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014; 129: 837–847.10.1161/CIRCULATIONAHA.113.005119CrossRefGoogle ScholarPubMed
Fordyce, CB, Roe, MT, Ahmad, T, et al. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol 2015; 65: 1567–1582.10.1016/j.jacc.2015.03.016CrossRefGoogle ScholarPubMed
Benjamin, EJ, Muntner, P, Alonso, A, et al. American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. heart disease and stroke statistics- 2019 update: a report from the american heart association. Circulation 2019; 139: e56–e528.10.1161/CIR.0000000000000659CrossRefGoogle ScholarPubMed
Haissaguerre, M, Jais, P, Shah, DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659–666.10.1056/NEJM199809033391003CrossRefGoogle ScholarPubMed
Calkins, H, Hindricks, G, Cappato, R, et al. 2017 HRS/EHRA/ECAS/APHRS/ SOLACE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018; 20: e1–e160.10.1093/europace/eux274CrossRefGoogle Scholar
Nishimura, RA, Vahanian, A, Eleid, MF, et al. Mitral valve disease--current management and future challenges. Lancet 2016; 387: 1324–1234.10.1016/S0140-6736(16)00558-4CrossRefGoogle ScholarPubMed
Whitlow, PL, Feldman, T, Pedersen, WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular valve Edge-to-Edge repair) high risk study. J Am Coll Cardiol 2012; 59: 130–139.10.1016/j.jacc.2011.08.067CrossRefGoogle ScholarPubMed
Lin, C, Liu, L, Liu, Y, et al. Recent developments in next-generation occlusion devices. Acta Biomater 2021; 128: 100–119.10.1016/j.actbio.2021.04.050CrossRefGoogle ScholarPubMed
Rigatelli, G, Dell’Avvocata, F, Ronco, F, et al. Patent oval foramen transcatheter closure: results of a strategy based on tailoring the device to the specific patient’s anatomy. Cardiol Young 2010; 20: 144–149. DOI 10.1017/S1047951109990631.Epub 2010-03-11.10.1017/S1047951109990631CrossRefGoogle Scholar
Regmi, MR, Lara Garcia, OE, Parajuli, P, et al. Late atrial thrombus formation after percutaneous patent foramen ovale closure. JACC Case Rep 2020; 2: 636–640.10.1016/j.jaccas.2020.01.010CrossRefGoogle ScholarPubMed
Hardt, SE, Eicken, A, Berger, F, et al. Closure of patent foramen ovale defects using Gore Cardioform septal occlude. Catheter Cardiovasc Interv 2017; 90: 824–829.10.1002/ccd.26993CrossRefGoogle Scholar
Gevorgyan Fleming, R, Kumar, P, West, B, et al. Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale. Catheter Cardiovasc Interv 2020; 95: 365–372.10.1002/ccd.28527CrossRefGoogle ScholarPubMed
Sommer, RJ, Love, BA, Paolillo, JA, et al. ASSURED clinical study: new GORE® CARDIOFORM ASD occluder for transcatheter closure of atrial septal defect. Catheter Cardiovasc Interv 2020; 5: 1285–1295.10.1002/ccd.28728CrossRefGoogle Scholar
Carroll, JD, Saver, JL, Thaler, DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092–1100.10.1056/NEJMoa1301440CrossRefGoogle ScholarPubMed
Krumsdorf, U, Ostermayer, S, Billinger, K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43: 302–329.10.1016/j.jacc.2003.10.030CrossRefGoogle ScholarPubMed
Chen, JZ, Thijs, VN. Atrial fibrillation following patent foramen ovale closure: systematic review and Meta-Analysis of observational studies and clinical trials. Stroke 2021; 52: 1653–1661.10.1161/STROKEAHA.120.030293CrossRefGoogle ScholarPubMed
Aladdin, J, Feghali, G, Jenkins, S, et al. Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale. J Invasive Cardiol 2006; 18: 365–368.Google Scholar
Chubb, H, Whitaker, J, Williams, SE, et al. Pathophysiology and management of arrhythmias associated with atrial septal defect and patent foramen ovale. Arrhythm Electrophysiol Rev 2014; 3: 168–172.10.15420/aer.2014.3.3.168CrossRefGoogle ScholarPubMed